Gastroenterology 2017-07-14T20:23:06+00:00


Targeted biologics, the recent emergence of innovative new oral therapies and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed.


Click the links below to download report overviews

Reports new KS-01

Quarterly survey of high dynamic markets, tracking brand usage, awareness, industry contacts and evolving perceptions.

RealTime Dynamix: IBD US 2017 (quarterly)
RealTime Dynamix: IBS US 2017 (bi-annual)

Reports new KS-02

In-depth analysis of a robust sample of patient journeys detailing the realities of current practice.

RealWorld Dynamix: Biologic Switching in IBD US 2017